Pulmonary Embolism Clinical Trial
— PERCEPICOfficial title:
Performance of the Pulmonary Embolism Rule-out Criteria (the PERC Rule) Combined With Implicit Low Clinical Probability (Gestalt) to Rule-out PE Without Further Exams
PERC rule was created to rule out pulmonary embolism (PE) without further exams, with
residual PE risk <2%. Its safety is currently confirmed in low PE prevalence populations as
north-American. In European high PE prevalence population, it has been showed that PERC rule
used alone or associated with low clinical probability assessed by revised Geneva score
(RGS) was not safe. In retrospective study, we suggest that the combination of PERC rule
with implicit clinical probability (gestalt) could allow the use of the PERC rule.
PERCEPIC, an observational prospective multicenter study performed in France and Belgium,
will test this hypothesis. Therefore, 3000 patients will be included in 12 centers. Primary
outcome will be the rate of thromboembolic events or death related or possibly related to PE
in patients with low implicit clinical probability and negative PERC rule (8 criteria
absents). Upper limit of confidence interval of this rate must be equal or lower than 3% to
consider PERC rule as safe in this combination.
Status | Completed |
Enrollment | 1773 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients admitted to the emergency department for one of the following criteria : - Dyspnea and/or Thoracic pain without another obvious cause - Pulmonary embolism suspicion whatever the reason Exclusion Criteria: - Age lower than 18 - Patients hospitalized for more than 48h - Ongoing curative anticoagulant therapy for more than 48h before admission - Patients with thromboembolic disease diagnosed before the admission - Unavailability for follow-up (short life expectancy, no phone number…) - Patient refusing to be contacted by phone at 3 month - Patient refusing that medical data were collected - Secondary exclusion criteria : curative anticoagulant therapy for more than 5 days during the 3 month follow-up for another reason than thromboembolic disease. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Belgium | Clinique Universitaire Saint-Luc | Bruxelles | |
Belgium | UH Erasme | Bruxelles | |
Belgium | UH Liège | Liège | |
France | Hospital of Agen | Agen | |
France | UH Angers | Angers | |
France | Hospital of Argenteuil | Argenteuil | |
France | UH Clermont-Ferrand | Clermont-Ferrand | |
France | Hospital of Le Mans | Le Mans | |
France | UH Nantes | Nantes | |
France | UH Poitiers | Poitiers | |
France | UH Rennes | Rennes | |
France | Hospital of Saint-Brieuc | Saint-Brieuc |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Belgium, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the accuracy of the combination of low implicit clinical probability (gestalt) and negative PERC rule (8 criteria absents) | Rate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule. Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination | 3 months | Yes |
Secondary | To assess usefulness of PERC and implicit low clinical probability combination to reduce the use of further exams | Mean number of further exams performed per diagnostic strategy | During emergency managment | No |
Secondary | To assess the accuracy of PERC and low clinical probability combination depending of clinical probability assessment method (implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score) | For each methods, AUC in receiver operating characteristic analyses of the 3-level classification scheme will be compared. | 3 months | No |
Secondary | To compare performances of clinical probability assessment methods : implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score | For each methods, AUC in receiver operating characteristic analyses of the 3-level classification scheme will be compared | 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|